Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC lowered its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 3.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 201,933 shares of the company’s stock after selling 6,273 shares during the quarter. Jackson Creek Investment Advisors LLC’s holdings in Amneal Pharmaceuticals were worth $1,599,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Amneal Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after acquiring an additional 378,136 shares during the period. State Street Corp increased its stake in shares of Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after purchasing an additional 127,753 shares in the last quarter. Hennessy Advisors Inc. raised its position in shares of Amneal Pharmaceuticals by 6.8% during the 4th quarter. Hennessy Advisors Inc. now owns 1,670,600 shares of the company’s stock worth $13,231,000 after purchasing an additional 106,600 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Amneal Pharmaceuticals by 9.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,539,934 shares of the company’s stock valued at $12,196,000 after buying an additional 135,051 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Amneal Pharmaceuticals by 149.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after buying an additional 777,568 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

AMRX has been the subject of a number of research analyst reports. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays lifted their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Piper Sandler increased their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.80.

Insider Buying and Selling

In other news, Director Gautam Patel sold 80,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the sale, the director now owns 1,888,886 shares in the company, valued at $15,375,532.04. This trade represents a 4.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 240,000 shares of company stock worth $2,004,000. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $8.76 on Friday. Amneal Pharmaceuticals, Inc. has a one year low of $5.18 and a one year high of $9.48. The stock has a market cap of $2.71 billion, a PE ratio of -12.88 and a beta of 1.10. The stock has a 50 day moving average price of $8.18 and a 200 day moving average price of $8.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The company had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same period last year, the business earned $0.14 earnings per share. As a group, analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.